Amgen Analyses Confirm Vectibix Provides Survival Benefit Over Chemotherapy

Biotech firm Amgen (AMGN) unveiled Monday morning studies which showed that colorectal cancer patients receiving Vectibix plus FOLFOX6 as first-line treatment achieved 43.4 months median overall survival, an increase of 11.4 months.

Vectibix is intended to treat patients with EGFR-expressing mCRC with non-mutated (wild-type) KRAS genes after failure of standard chemotherapy regimens.

“Data from these retrospective analyses are helping Amgen make important connections between tumor biology and treatment outcomes,” said Sean Harper, executive vice president of Research and Development at Amgen.

Colorectal cancer is the second most common cancer in women, and the third in men worldwide, with approximately 1.4 million new cases occurring each year.

Leave a Comment